Mitomycin‐C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy

Aman U. Buzdar; Charles K. Tashima; George R. Blumenschein; Gabriel N. Hortobagyi; Hwee‐Yong ‐Y Yap; Allan N. Krutchik; Gerald P. Bodey; Robert B. Livingston

doi:10.1002/1097-0142(197802)41:2<392::AID-CNCR2820410202>3.0.CO;2-7

Mitomycin‐C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy

Aman U. Buzdar
, Charles K. Tashima
, George R. Blumenschein
, Gabriel N. Hortobagyi
, Hwee‐Yong ‐Y Yap
, Allan N. Krutchik
, Gerald P. Bodey
, Robert B. Livingston

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

Fifty patients with breast cancer refractory to endocrine manipulation and/or combination chemotherapy were treated with mitomycin‐C 20 mg/m² I.V. every 4–6 weeks and megestrol acetate 160 mg daily. Of 48 evaluable patients, 4% achieved complete remission (CR), 23% had partial remission (PR). Median duration of response for CR and PR was 7 months. Non‐responders had a median survival of 2 months. The difference in survival of responders (both CR and PR) and non‐responders was statistically significant at p<0.01 level. Attenuated doses of mitomycin‐C were administered at increasing intervals due to cumulative myelosuppressive toxicity.

Original language	English (US)
Pages (from-to)	392-395
Number of pages	4
Journal	Cancer
Volume	41
Issue number	2
DOIs	https://doi.org/10.1002/1097-0142(197802)41:2<392::AID-CNCR2820410202>3.0.CO;2-7
State	Published - Feb 1978
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/1097-0142(197802)41:2<392::AID-CNCR2820410202>3.0.CO;2-7

Cite this

@article{1c4a62dc6bc04a0ba5f9f7b63b59a681,

title = "Mitomycin‐C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy",

abstract = "Fifty patients with breast cancer refractory to endocrine manipulation and/or combination chemotherapy were treated with mitomycin‐C 20 mg/m2 I.V. every 4–6 weeks and megestrol acetate 160 mg daily. Of 48 evaluable patients, 4\% achieved complete remission (CR), 23\% had partial remission (PR). Median duration of response for CR and PR was 7 months. Non‐responders had a median survival of 2 months. The difference in survival of responders (both CR and PR) and non‐responders was statistically significant at p<0.01 level. Attenuated doses of mitomycin‐C were administered at increasing intervals due to cumulative myelosuppressive toxicity.",

author = "Buzdar, \{Aman U.\} and Tashima, \{Charles K.\} and Blumenschein, \{George R.\} and Hortobagyi, \{Gabriel N.\} and Yap, \{Hwee‐Yong ‐Y\} and Krutchik, \{Allan N.\} and Bodey, \{Gerald P.\} and Livingston, \{Robert B.\}",

year = "1978",

month = feb,

doi = "10.1002/1097-0142(197802)41:2<392::AID-CNCR2820410202>3.0.CO;2-7",

language = "English (US)",

volume = "41",

pages = "392--395",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

TY - JOUR

T1 - Mitomycin‐C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy

AU - Buzdar, Aman U.

AU - Tashima, Charles K.

AU - Blumenschein, George R.

AU - Hortobagyi, Gabriel N.

AU - Yap, Hwee‐Yong ‐Y

AU - Krutchik, Allan N.

AU - Bodey, Gerald P.

AU - Livingston, Robert B.

PY - 1978/2

Y1 - 1978/2

N2 - Fifty patients with breast cancer refractory to endocrine manipulation and/or combination chemotherapy were treated with mitomycin‐C 20 mg/m2 I.V. every 4–6 weeks and megestrol acetate 160 mg daily. Of 48 evaluable patients, 4% achieved complete remission (CR), 23% had partial remission (PR). Median duration of response for CR and PR was 7 months. Non‐responders had a median survival of 2 months. The difference in survival of responders (both CR and PR) and non‐responders was statistically significant at p<0.01 level. Attenuated doses of mitomycin‐C were administered at increasing intervals due to cumulative myelosuppressive toxicity.

AB - Fifty patients with breast cancer refractory to endocrine manipulation and/or combination chemotherapy were treated with mitomycin‐C 20 mg/m2 I.V. every 4–6 weeks and megestrol acetate 160 mg daily. Of 48 evaluable patients, 4% achieved complete remission (CR), 23% had partial remission (PR). Median duration of response for CR and PR was 7 months. Non‐responders had a median survival of 2 months. The difference in survival of responders (both CR and PR) and non‐responders was statistically significant at p<0.01 level. Attenuated doses of mitomycin‐C were administered at increasing intervals due to cumulative myelosuppressive toxicity.

UR - https://www.scopus.com/pages/publications/0017801135

UR - https://www.scopus.com/pages/publications/0017801135#tab=citedBy

U2 - 10.1002/1097-0142(197802)41:2<392::AID-CNCR2820410202>3.0.CO;2-7

DO - 10.1002/1097-0142(197802)41:2<392::AID-CNCR2820410202>3.0.CO;2-7

M3 - Article

C2 - 630529

AN - SCOPUS:0017801135

SN - 0008-543X

VL - 41

SP - 392

EP - 395

JO - Cancer

JF - Cancer

IS - 2

ER -

Mitomycin‐C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this